tacalcitol in the treatment of acquired perforating collagenosis
Clicks: 9
ID: 240511
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
2.4
/100
9 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #35 of 35 articles by views in the american journal of the medical sciences
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Acquired perforating collagenosis (APC) is a rare perforating dermatosis characterized by transepidermal collagen elimination. We describe a 65-year-old patient, with long-standing type 2 diabetes mellitus and a 2-year history of itchy hyperkeratotic nodules situated on the back, who was subsequently diagnosed with APC. Treatment included topical corticosteroids and antihistamines, without improvement of the lesions. However, therapy with topical tacalcitol administered for 2 months produced a significant response leading to complete remission of APC.
| Reference Key |
escribano-stabl2014casetacalcitol
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;J.C. Escribano-Stablé;C. Doménech;J. Matarredona;J.C. Pascual;A. Jaen;J. Vicente |
| Journal | the american journal of the medical sciences |
| Year | 2014 |
| DOI |
10.1159/000360390
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.